secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001615219-25-000125
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius regains Nasdaq bid price compliance; merger with Decoy ongoing
-----------------------------------------------------------------------

- Regained compliance with Nasdaq's minimum bid price requirement on Sept. 4, 2025.
- Subject to one-year Mandatory Panel Monitor; delisting risk if bid price falls below $1.00 again.
- Must also comply with Nasdaq equity standard by Oct. 20, 2025; currently noncompliant.
- Planned merger with Decoy Therapeutics to combine into Decoy Therapeutics, led by Decoy's co-founders.
- Decoy aims to file IND for pan-coronavirus antiviral within 12 months and advance other pipeline programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000125/0001615219-25-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000125/flks-20250904.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer